Kokal W A, Duda R B, Azumi N, Sheibani K, Kemeny M M, Terz J J, Harada J R
Arch Surg. 1986 Dec;121(12):1434-9. doi: 10.1001/archsurg.1986.01400120084014.
We performed this study to determine if tumor DNA content was an independent prognostic indicator in patients with primary tumors or hepatic metastases from colorectal cancer. We analyzed tumor DNA content by flow cytometry from paraffin-embedded specimens in 133 patients. In the 77 patients with primary colorectal cancer who had had "curative" resection, DNA content of the tumor was an independent prognostic indicator in predicting both relapse-free and overall survival. Logistics regression analysis demonstrated that aneuploidy, ie, tumors that exhibited a population of cells with an "abnormal" DNA content, was the single most important variable in predicting both recurrence and death from disease, even more important than stage. However, in 56 patients with hepatic metastases from colorectal cancer, the DNA content of the liver metastases bore no relationship to the patients' survival or their response to therapy. These data suggest that tumor DNA content is an important prognostic indicator in patients with primary colorectal carcinoma but does not reflect the natural history of patients with liver metastases.
我们开展这项研究以确定肿瘤DNA含量是否为原发性肿瘤或结直肠癌肝转移患者的独立预后指标。我们通过流式细胞术分析了133例患者石蜡包埋标本中的肿瘤DNA含量。在77例行“根治性”切除的原发性结直肠癌患者中，肿瘤的DNA含量是预测无复发生存期和总生存期的独立预后指标。逻辑回归分析表明，非整倍体，即表现出一群具有“异常”DNA含量细胞的肿瘤，是预测疾病复发和死亡的唯一最重要变量，甚至比分期更重要。然而，在56例结直肠癌肝转移患者中，肝转移灶的DNA含量与患者的生存率或对治疗的反应无关。这些数据表明，肿瘤DNA含量是原发性结直肠癌患者的重要预后指标，但不能反映肝转移患者的自然病程。
